Ovid Therapeutics Inc (NASDAQ:OVID) – Research analysts at William Blair issued their Q1 2018 earnings per share estimates for shares of Ovid Therapeutics in a report issued on Wednesday. William Blair analyst T. Lugo forecasts that the company will earn ($0.48) per share for the quarter. William Blair also issued estimates for Ovid Therapeutics’ Q2 2018 earnings at ($0.54) EPS, Q3 2018 earnings at ($0.59) EPS and Q4 2018 earnings at ($0.58) EPS.

Separately, Zacks Investment Research upgraded Ovid Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Five equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $19.33.

Ovid Therapeutics (OVID) opened at $11.52 on Friday. Ovid Therapeutics has a 12-month low of $5.28 and a 12-month high of $15.93.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.16.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new position in shares of Ovid Therapeutics in the second quarter worth $135,000. TIAA CREF Investment Management LLC bought a new position in shares of Ovid Therapeutics in the second quarter worth $142,000. Schwab Charles Investment Management Inc. bought a new position in shares of Ovid Therapeutics in the second quarter worth $153,000. OxFORD Asset Management LLP bought a new position in shares of Ovid Therapeutics in the second quarter worth $189,000. Finally, Citadel Advisors LLC bought a new position in shares of Ovid Therapeutics in the second quarter worth $204,000. Institutional investors own 29.36% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/02/research-analysts-issue-forecasts-for-ovid-therapeutics-incs-q1-2018-earnings-ovid.html.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Earnings History and Estimates for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Stock Ratings for Ovid Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics Inc and related stocks with our FREE daily email newsletter.